This article is more than 5 years old. Information may no longer be current.
NovaBay discontinues studies on NVC-422 for viral conjunctivitis
NovaBay Pharmaceuticals announced in a press release that its phase 2 clinical study for NVC-422 ophthalmic formulation for patients with adenoviral conjunctivitis did not meet primary or secondary endpoints.
The endpoints included clearing of bulbar conjunctival injection, eradication of adenovirus from the tear film, spread of infection to the fellow eye, reduction in subepithelial infiltrates and clearing of blurred vision compared to its vehicle at test-of-cure-visit (day 18), according to the press release.
No significant adverse events were reported.
For viral conjunctivitis, NovaBay does not plan to initiate any new studies of NVC-422.
According to the press release, the company is focusing on the commercial launch of NovaBay’s i-Lid Cleanser, supporting Pioneer Pharma in the commercial launch of NeutroPhase in China (pending regulatory approval) and the clinical development of NVC-422 irrigation solution for blockage and encrustation in indwelling long-term urinary catheters.